[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585792":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":20,"centralContacts":25,"locations":19,"responsibleParty":31,"collaborators":19,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":37,"acronym":38,"eligibilityCriteria":39,"healthyVolunteers":35,"sex":40,"minAge":41,"maxAge":19,"enrollmentInfo":42,"targetDuration":19,"studyType":45,"phases":46,"briefSummary":48,"conditions":49,"keywords":19,"overallStatus":51,"whyStopped":19,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":19},{"fullName":5,"class":6},"Assistance Publique Hopitaux De Marseille","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Patient with acute myeloid leukemia","Adult patient with acute myeloid for whom an additionnal 20 mL of blood will be collected.",[12],"Procedure: blood sampling",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"PROCEDURE","blood sampling","Patients will be seen in hospital as part of their routine care, during which a blood test will be prescribed. On this occasion, an additional 20 mlof blood will be collected for research purposes.",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Régis Costello, Professor","Assitance Public - Hôpitaux de Marseille","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},"clement PIERRE, PhD","CONTACT","+33491435796","clement.pierre@ap-hm.fr",{"type":32,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100585792","single-cell-acute-leukemia-analysis-100585792",false,"NCT06906978","Single Cell Acute Leukemia Analysis","SCALA","Inclusion Criteria:\n\n* Adult patient\n* Patient who has received information about the study and has not expressed opposition,\n* Patients who are beneficiaries of a social security plan,\n* Patient with relapsed or refractory acute myeloid leukemia, whatever the previous treatment, the therapeutic line and the time between the previous treatment and the relapse.\n\nExclusion Criteria:\n\n* Persons who do not understand the French language if there is no translator available to translate for them.\n* Absence of circulating blastosis.","ALL","18 Years",{"count":43,"type":44},40,"ESTIMATED","INTERVENTIONAL",[47],"NA","Numerous chemotherapy and immunotherapy resistance genes have been identified in cancers in general and acute myeloid leukemia in particular. As a preliminary to this study, the investigators hypothesized the co-expression of these genes in the same cell as a major factor in relapse. This hypothesis was supported in vitro by the study of the evolution of these co-expressions after incubation with chemotherapy drugs. The current study aims to verify this hypothesis by studying the expression of these genes in single-cell samples from relapsed acute myeloid leukemia patients.",[50],"Acute Myeloid Leucemia","NOT_YET_RECRUITING","2025-04-08",{"date":54,"type":55},"2025-04-10","ACTUAL",{"date":57,"type":44},"2025-07-31",{"date":59,"type":44},"2029-07-31",{"name":5,"class":6}]